KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Equity Ratio (2016 - 2025)

Jazz Pharmaceuticals has reported Equity Ratio over the past 16 years, most recently at 0.37 for Q4 2025.

  • Quarterly Equity Ratio rose 8.69% to 0.37 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.37 through Dec 2025, up 8.69% year-over-year, with the annual reading at 0.37 for FY2025, 8.69% up from the prior year.
  • Equity Ratio was 0.37 for Q4 2025 at Jazz Pharmaceuticals, up from 0.35 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.56 in Q1 2021 and troughed at 0.26 in Q3 2022.
  • The 5-year median for Equity Ratio is 0.32 (2024), against an average of 0.33.
  • Biggest five-year swings in Equity Ratio: plummeted 45.45% in 2022 and later grew 17.81% in 2023.
  • Tracing JAZZ's Equity Ratio over 5 years: stood at 0.32 in 2021, then decreased by 11.67% to 0.28 in 2022, then increased by 15.17% to 0.33 in 2023, then rose by 3.9% to 0.34 in 2024, then rose by 8.69% to 0.37 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.37, 0.35, and 0.34 for Q4 2025, Q3 2025, and Q2 2025 respectively.